SCHEMBL4501291

SCHEMBL4501291

CCCc1ccc(S(=O)(=O)NC(C)CCc2ccccc2)cc1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.81
CYP1A2 P05177 1/20 0.81
CYP2C9 P11712 1/20 0.81
CYP2C19 P33261 1/20 0.81
POLB P06746 1/20 0.71
SMN1; SMN2 Q16637 1/20 0.66
L3MBTL1 Q9Y468 1/20 0.58
NR3C1 P04150 2/20 0.58
CA12 O43570 1/20 0.56
CA2 P00918 1/20 0.56
CA9 Q16790 1/20 0.56
MMP2 P08253 1/20 0.53
MMP7 P09237 1/20 0.53
MMP9 P14780 1/20 0.53
MMP8 P22894 1/20 0.53
MMP13 P45452 1/20 0.53
MMP14 P50281 1/20 0.53
NPSR1 Q6W5P4 1/20 0.49
CNR2 P34972 1/20 0.46
SIGMAR1 Q99720 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13889012 0.87 ALDH1A1 (0.83) ALDH1A1CYP1A2CYP2C9CYP2C19POLB
SCHEMBL4513298 0.86 ALDH1A1 (0.81) ALDH1A1CYP1A2CYP2C9CYP2C19POLB
SCHEMBL4515726 0.86 ALDH1A1 (0.81) ALDH1A1CYP1A2CYP2C9CYP2C19POLB
SCHEMBL4504396 0.84 ALDH1A1 (0.73) ALDH1A1CYP1A2CYP2C9CYP2C19POLB
SCHEMBL4512039 0.83 ALDH1A1 (0.76) ALDH1A1CYP1A2CYP2C9CYP2C19POLB
SCHEMBL4517771 0.83 ALDH1A1 (0.81) ALDH1A1CYP1A2CYP2C9CYP2C19POLB
SCHEMBL28001450 0.83 ALDH1A1 (0.81) ALDH1A1CYP1A2CYP2C9CYP2C19POLB
SCHEMBL4507266 0.83 ALDH1A1 (0.71) ALDH1A1CYP1A2CYP2C9CYP2C19POLB
SCHEMBL4520301 0.82 ALDH1A1 (0.74) ALDH1A1CYP1A2CYP2C9CYP2C19POLB
SCHEMBL5272724 0.82 ALDH1A1 (0.74) ALDH1A1CYP1A2CYP2C9CYP2C19POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090093485-A1 Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases ASTRAZENECA AB (SE) 2009-04-09 US disclosed
US-20090093485-A1 Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases ASTRAZENECA AB (SE) 2009-04-09 US disclosed
US-20090093485-A1 Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases ASTRAZENECA AB (SE) 2009-04-09 US disclosed
EP-1807391-A1 NOVEL SULPHONAMIDE DERIVATIVES AS GLUCOCORTICOID RECEPTOR MODULATORS FOR THE TREATMENT OF INFLAMMATORY DISEASES AstraZeneca AB (SE) 2007-07-18 EP disclosed
WO-2006046916-A1 NOVEL SULPHONAMIDE DERIVATIVES AS GLUCOCORTICOID RECEPTOR MODULATORS FOR THE TREATMENT OF INFLAMMATORY DISEASES ASTRAZENECA AB (SE) 2006-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090093485-A1 Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases NR3C1, NR3C2, NR5A1 ALDH1A1 2398/4885CYP1A2 1231/4885CYP2C9 368/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.